Loading...
In this study, researchers evaluated the cost-effectiveness of early treatment of intracerebral hemorrhage (ICH) with the hemostatic recombinant activated factor VII (rFVIIa). The data used for the analysis came from a randomized, dose-ranging clinical trial of rFVIIa in ICH (N Engl J Med 2005; 352:777). In the current, manufacturer-funded study, the authors used decision-analysis models to estimate lifetime costs and outcomes in the 399 patients with spontaneous ICH who had been randomized to either standard care (i.e., not including rFVIIa) or one of three doses (40, 80, or 160 μg/kg) of rFVIIa within 4 hours of symptom onset. The outcomes included incremental cost per life-year saved and per quality-adjusted life-year (QALY) gained.
Despi…